AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 251 min read$MLYS

Slingsby Brian Taylor sold $3.0M of MLYS (indirect holdings)

Slingsby Brian Taylor sold 104,320 indirectly-held shares of Mineralys Therapeutics, Inc. (MLYS) at $28.81 ($3.01M total) on 2026-09-22.

Original reporting
SEC EDGAR · Slingsby Brian Taylor
Published Sep 25, 2026, 1:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 1:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MLYS
Bearish
medium confidence
Mentioned
$MLYS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLYSBearishLow
01

Why it matters

The filing provides fresh, material information about insider sentiment, which traders may use to adjust short‑term positions.

02

Market read

Insider sale of this size is a primary disclosure that can influence short‑term price action for MLYS.

03

What to watch

Potential upcoming clinical data releases that may offset the sale's impact.

Relevance 6/10Novelty 4/10Timing: post-market filing

Background

Form 4 filings disclose insider transactions; a director's sale of $3M is noteworthy for a micro‑cap biotech.

Company-level read

Ticker impact

$MLYSBearishMedium confidence
Context

Director Brian Taylor sold 104,320 shares of Mineralys Therapeutics for $3.0M via a Form 4 filing.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A $3M sale by a director is material for a micro‑cap biotech, but no other catalyst is present.

Market effects

Sector

Limited impact on the broader biotech sector; similar insider sales are common.

Regional

No significant regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • company
    Mineralys Therapeutics, Inc.

    Biotech company listed on NASDAQ under ticker MLYS.

  • person
    Brian Taylor

    Director of Mineralys Therapeutics who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MLYS insider trading history →

Related articles

AUG 22
$MLYSMed

Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention

Mineralys Therapeutics (MLYS) reported a Q2 2026 net loss of $241.07M. The company appointed James J. Ferguson III, M.D., as Chief Medical Officer. Shares are down 5.04% in 30 days and 14.07% in 90 days, but up 72.32% in 1 year and 97.31% in 3 years. Analysts suggest fair value at $50.88, above the current $25.65, based on lorundrostat's potential. Risks include regulatory outcomes and cash burn.

simplywall.st2 min
AUG 19
$MLYSMed

Mineralys (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics (MLYS) reported Q2 2026 earnings, highlighting a net loss of $241.1 million due to royalty repurchase obligations. Key financial activities included a $150 million equity offering and a $100 million tranche from a $500 million loan. The company is preparing for the FDA's PDUFA date for lorundrostat, a hypertension treatment, with commercial launch plans and payer discussions underway. Management expressed optimism about the regulatory review and market potential.

fool.com4 min
AUG 13
$MLYSMed

Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary

Mineralys Therapeutics reported Q2 2026 updates on lorundrostat. The company said it repurchased future royalties from Mitsubishi Tanabe for $200 million, secured a $500 million senior secured term loan, and completed a $150 million equity offering. R&D rose to $221.4 million. It cited LAUNCH-HTN results and targeted a Dec. 22, 2026 PDUFA, with FDA discussions in Oct-Nov 2026.

yahoo.com7 min
AUG 11
$MLYSMed

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics (MLYS) discussed exploratory proteomic biomarker results from its Launch-HTN and Advance-HTN trials at ENDO 2026, with management saying lorundrostat was linked to reductions in heart-failure risk biomarkers. The company expects FDA discussions to intensify near the October-November PDUFA window, and outlined U.S. payer and physician outreach ahead of a December PDUFA launch. Q2 cash was $661.4M; net loss was $241.1M.

yahoo.com6 min
AUG 11
$MLYSMedAI 8/10

Why is Mineralys Therapeutics stock sliding today?

Investing.com reports Mineralys Therapeutics (MLYS) shares fell 4.9% in after-hours after posting a Q2 2026 per-share loss of $2.85 versus a $2.63 analyst consensus. The loss followed a rise in operating costs, including $221.4 million R&D and a $200 million upfront payment to Tanabe for lorundrostat royalty buyout. FDA PDUFA is Dec. 22, 2026.

investing.com4 min
AUG 11
$MLYSMed

Mineralys Therapeutics, Inc. (MLYS): Results of Operations and Financial Condition

Mineralys Therapeutics, Inc. (MLYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update – PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine e

SEC EDGAR 8-K6 min